Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

47P - Platinum rechallenge (PtRc) for high-grade epithelial ovarian cancer (HGEOC) patients (pts) considered not eligible for further platinum therapy (former platinum-resistant).

Date

23 Feb 2023

Session

Poster Display session

Presenters

David Illescas

Citation

Annals of Oncology (2023) 8 (1suppl_1): 100811-100811. 10.1016/esmoop/esmoop100811

Authors

D. Illescas1, J.F. Grau Béjar2, V. Navarro3, L. Fariñas Madrid4, A.A. Valdivia4, G. Villacampa Javierre3, C. Garcia Duran4, A. Oaknin4

Author affiliations

  • 1 Barcelona/ES
  • 2 Institut Gustave Roussy - INSERM UMR 981, Villejuif/FR
  • 3 Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona/ES
  • 4 Vall d'Hebron University Hospital, Barcelona/ES

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 47P

Background

Platinum sensitivity may be a dynamic status in HGEOC pts. Currently, higher proportion of platinum-resistant (PR) pts exceeds the predicted median OS of 12 months (m) with an ECOG PS 0-1, and PtRc may be still an option. We aimed at evaluating the efficacy of retreating with platinum to HGEOC pts considered PR based solely on platinum-free interval (PFI) <6 m and exploring clinical and molecular predictive markers.

Methods

This is an ambispective observational, single-institution study that assessed PtRc efficacy in pts for whom last PFI was < 6 m and received non-platinum agents afterward for >1 year. Key clinical characteristics and BRCA mutation (BRCA-mut) data were analyzed from medical charts between 2010 and 2022. Objective response rate (ORR) and median progression-free survival (mPFS) were evaluated in the whole population, and according to BRCA status and prior number of lines.

Results

At time of data cut-off, 58 pts were included in the analysis. Median age was 57 years (IQR 48-63), 96.4% had ECOG <1, 93% had high-grade serous histology and 11 pts (18.9%) harbored tBRCA-mut. Median number of lines prior to PtRc were 6 (IQR 5-7), and median PFI prior to PtRc was 24.8m (IQR 19.7-33.5). Platinum doublets used in PtRc contained: paclitaxel (41.4%), PLD (39.7%), gemcitabine (15.5%); or carboplatin alone (3.4%). In the whole cohort, ORR was 56.9% (95%CI 43.2-69.8) and mPFS was 6.9m (95%CI 5.8-8.3). Improved PFS and ORR were observed in tBRCA-mut compared to BRCA wild type (wt) pts: ORR 81.8% (95%CI 48.2-97.7) vs 51.1% (95%CI 36.0-65.9, p=0.08), mPFS 9.0 vs 6.7m (HR 0.39, 95%CI 0.18-0.85; p=0.02), respectively. According to number lines prior to PtRc (4), ORR was 76% (95%CI 54.9-90.6) vs 42.4% (95%CI 25.5-60.8; p=0.01), and mPFS 7.7m vs 6.7m (HR 0.57, 95%CI 0.32-1.0; p=0.05).

Conclusions

PtRc seemed to be an efficacious therapeutic approach for pts previously classified as PR who had received non-platinum therapies for >1 year, especially for those harboring tBRCA-mut or having received

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

D. García-Illescas: Non-Financial Interests, Personal, Training: Merck, GSK, LEO Pharma. L. Fariñas Madrid: Non-Financial Interests, Personal, Speaker’s Bureau: AstraZeneca, MSD, Clovis, Roche; Non-Financial Interests, Personal, Advisory Board: GSK, Clovis; Non-Financial Interests, Personal, Other, Travel/accomodation/expenses: AstraZeneca-MSD, Roche, GSK, Ability Pharma. A.A. Valdivia: Non-Financial Interests, Personal, Other, Travel/accommodation expenses: Merck; Non-Financial Interests, Personal, Speaker’s Bureau: Pfizer, Jansen, AstraZeneca. C. Garcia Duran: Non-Financial Interests, Personal, Speaker’s Bureau: GSK, AstraZeneca, MSD. A. Oaknin: Non-Financial Interests, Personal, Advisory Board: Agenus, AstraZeceneca Clovis Oncology, Inc., Corcept Therapeutics, Deciphera Pharmaceutical, Eisai Europe Limited, EMD Serono, Inc., F. Hoffmann-La Roche, GlaxoSmithKline, GOG, Immunogen, Medison Pharma, Merck Sharp & Dohme de España, Mersana Therapeutic; Non-Financial Interests, Personal, Other, Travel/accommodation: Roche, AstraZeneca, PharmaMar, GSK and Clovis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.